Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Inventory (2016 - 2025)

Historic Inventory for Usana Health Sciences (USNA) over the last 15 years, with Q3 2025 value amounting to $90.8 million.

  • Usana Health Sciences' Inventory rose 4188.08% to $90.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.8 million, marking a year-over-year increase of 4188.08%. This contributed to the annual value of $69.7 million for FY2024, which is 1347.51% up from last year.
  • Latest data reveals that Usana Health Sciences reported Inventory of $90.8 million as of Q3 2025, which was up 4188.08% from $83.3 million recorded in Q2 2025.
  • In the past 5 years, Usana Health Sciences' Inventory ranged from a high of $98.3 million in Q1 2022 and a low of $60.1 million during Q3 2023
  • For the 5-year period, Usana Health Sciences' Inventory averaged around $76.5 million, with its median value being $71.6 million (2024).
  • As far as peak fluctuations go, Usana Health Sciences' Inventory surged by 4470.68% in 2021, and later tumbled by 3391.13% in 2023.
  • Usana Health Sciences' Inventory (Quarter) stood at $96.3 million in 2021, then tumbled by 30.34% to $67.1 million in 2022, then decreased by 8.4% to $61.5 million in 2023, then rose by 13.48% to $69.7 million in 2024, then skyrocketed by 30.18% to $90.8 million in 2025.
  • Its Inventory was $90.8 million in Q3 2025, compared to $83.3 million in Q2 2025 and $73.6 million in Q1 2025.